


## Macimorelin acetate

Cat. No.:	HY-14820A		
CAS No.:	945212-59-9		
Molecular Formula:	C <sub>28</sub> H <sub>34</sub> N <sub>6</sub> O <sub>5</sub>		
Molecular Weight:	534.61		
Target:	GHSR		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (187.05 mM; Need ultrasonic)					
	Preparing Stock Solutions	<div><div>Solvent</div><div>Concentration</div></div>	Mass	1 mg	5 mg	10 mg
		1 mM		1.8705 mL	9.3526 mL	18.7052 mL
		5 mM		0.3741 mL	1.8705 mL	3.7410 mL
		10 mM		0.1871 mL	0.9353 mL	1.8705 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.68 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (4.68 mM); Clear solution					

### BIOLOGICAL ACTIVITY

Description	Macimorelin (EP-1572) acetate, a GH secretagogue, is an orally active GHSR agonist. Macimorelin acetate stimulates GH release. Macimorelin acetate can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS) <sup>[1][2][3]</sup> .
IC <sub>50</sub> & Target	GHSR <sup>[1]</sup>
In Vivo	Macimorelin (5 mg/kg, i.p. twice daily for 2 weeks) acetate decreased the number and duration of seizures in IHKA mouse model <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Intrahippocampal kainic acid (IHKA) mouse model <sup>[2]</sup>
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection (i.p.), twice daily for 2 weeks.
Result:	Significantly decreased the number and duration of seizures during the treatment period, but had no antiepileptogenic or disease-modifying effect.

## REFERENCES

- [1]. Jose M Garcia, et al. Macimorelin as a Diagnostic Test for Adult GH Deficiency. J Clin Endocrinol Metab. 2018 Aug 1;103(8):3083-3093.
- [2]. An Buckinx, et al. Translational potential of the ghrelin receptor agonist macimorelin for seizure suppression in pharmacoresistant epilepsy. Eur J Neurol. 2021 Sep;28(9):3100-3112.
- [3]. Ali SA, Garcia JM. Randomized clinical trial of the novel oral ghrelin mimetic macimorelin in the treatment of cancer cachexia: study design and preliminary results. Endocr Rev. 2013;34:

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA